View More View Less
  • 1 Semmelweis Egyetem, Általános Orvostudományi Kar, Budapest, Pf. 2, 1428
  • 2 Semmelweis Egyetem, Általános Orvostudományi Kar, Budapest

Összefoglaló. A cukorbetegség és a depresszió világszerte népbetegség. Mindkettő kialakulása multifaktoriális, amelyben szerepet játszhatnak külső, környezeti tényezők, valamint belső, a szervezetben játszódó folyamatok, többek között különböző gének nem megfelelő működése. Bár a diabetes és a depresszió komorbiditása jól ismert, a két betegség hátterében zajló folyamatok, illetve ezen folyamatok egymásra hatása nem minden részletet illetően tisztázott. A szerzők összefoglaló közleményének célja bemutatni a 2-es típusú cukorbetegség és a depresszió közötti kétirányú kapcsolat hátterében álló ismert és még csak feltételezett mechanizmusokat, illetve felhívni a figyelmet a két betegség egyidejű szűrésének és kezelésének fontosságára, hiszen együttes fennállásukkor nőhet a morbiditás és a mortalitás. A cukorbetegek depresszióra irányuló szűrésével és a depressziós betegek diabetes irányú kivizsgálásával csökkenthető lehet a komorbiditásból származó komplikációk és szövődmények, illetve a kezelési nehézségek előfordulása. A két betegség ellátásában fontos szerepe van a családorvosnak, aki a korai diagnózissal és kezeléssel javíthatja a betegek életminőségét, lassíthatja a betegségek progresszióját és a szövődmények kialakulásának kockázatát. Orv Hetil. 2019; 160(21): 807–814.

Summary. Diabetes and depression are considered global epidemics. Both have multifactorial aetiologies, including external, environmental factors and internal factors in connection with physiological processes as well as genetic variants triggering disease onset. Although the co-occurrence of diabetes and depression is well described, the mechanisms underlying these diseases and their interactions are still not entirely revealed. The authors aimed to present known and potential explanations of the co-occurrence of these diseases and to highlight the importance of their timely diagnosis and effective treatment, as their co-occurrence may increase morbidity and mortality. Screening for depression among diabetes patients and for diabetes among patients with depression may decrease the incidence of complications and consequences of this comorbidity and may foster more effective treatment. General practitioners play a key role in the care of both diseases by providing timely diagnosis and adequate treatment potentially leading to a better quality of life, slower disease progression and decreased risk of complications. Orv Hetil. 2019; 160(21): 807–814.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1

    International Diabetes Federation. IDF Diabetes Atlas. Eight edition, 2017. Available from: http://www.diabetesatlas.org [accessed: December 10, 2018].

  • 2

    Jermendy G, Nádas J, Szigethy E, et al. Prevalence rate of diabetes mellitus and impaired fasting glycemia in Hungary: cross-sectional study on nationally representative sample of people aged 20–69 years. Croat Med J. 2010; 51: 151–156.

  • 3

    Kempler P, Putz Zs, Kiss Z, et al. Prevalence and financial burden of type 2 diabetes mellitus in Hungary between 2001–2014 – results of the analysis of the National Health Insurance Fund database. [A 2-es típusú diabetes előfordulása és költségterheinek alakulása Magyarországon 2001–2014 között – az Országos Egészségbiztosítási Pénztár adatbázis-elemzésének eredményei.] Diab Hung. 2016; 24: 177–188. [Hungarian]

  • 4

    World Health Organization. Diabetes country profiles 2016. Hungary. WHO, Geneva. Available from: https://www.who.int/diabetes/country-profiles/hun_en.pdf?ua=1 [accessed: December 10, 2018].

  • 5

    Vámos EP, Kopp MS, Keszei A, et al. Prevalence of diabetes in a large, nationally representative population sample in Hungary. Diabetes Res Clin Pract. 2008; 81: e5–E8.

  • 6

    Domján BA, Ferencz V, Tänczer T, et al. Large increase in the prevalence of self-reported diabetes based on a nationally representative survey in Hungary. Prim Care Diabetes 2017; 11: 107–111.

  • 7

    World Health Organization. Depression and other common mental disorders. Global Health Estimates. WHO, Geneva, 2017. Available from: http://www.who.int/mental_health/management/depression/prevalence_global_health_estimates/en/ [accessed: December 10, 2018].

  • 8

    World Federation for Mental Health. DEPRESSION: A global crisis. World Mental Health Day, October 10 2012. WHO, Geneva. Available from: http://www.who.int/mental_health/management/depression/wfmh_paper_depression_wmhd_2012.pdf [accessed: December 10, 2018].

  • 9

    Szádóczky E, Rihmer Z, Papp Z, et al. The prevalence of affective and anxiety disorders in primary care practice in Hungary. J Affect Disord. 1997; 43: 239–244.

  • 10

    Rihmer Z, Gonda X, Eőry A, et al. Screening of depression in primary care in Hungary and its importance in suicide prevention. [A depresszió szűrése az alapellátásban Magyarországon és ennek jelentősége az öngyilkosság megelőzésében.] Psychiatr Hung. 2012; 27: 224–232. [Hungarian]

  • 11

    Torzsa P, Rihmer Z, Gonda X, et al. Family history of suicide: a clinical marker for major depression in primary care practice? J Affect Disord. 2009; 117: 202–204.

  • 12

    Siu AL, US Preventive Services Task Force (USPSTF). Screening for depression in adults: US Preventive Services Task Force Recommendation Statement. JAMA 2016; 315: 380–387.

  • 13

    O’Connor E, Rossom RC, Henninger M, et al. Primary care screening for and treatment of depression in pregnant and postpartum women: evidence report and systematic review for the US Preventive Services Task Force. JAMA 2016; 315: 388–406.

  • 14

    Rihmer Z, Rutz W. Treatment of attempted suicide and suicidal patients in primary care. In: Wasserman D, Wasserman C. (eds.) Oxford Textbook of Suicidology and Suicide Prevention. Oxford University Press, Oxford, 2009; pp. 463–470.

  • 15

    Eurostat Statistics Explained. Causes of death – standardised death rate, 2015 (per 100 000 inhabitants) HLTH18.png. Eurostat, Luxembourg. Available from: https://ec.europa.eu/eurostat/statistics-explained/index.php?title=File:Causes_of_death_%E2%80%94_standardised_death_rate,_2015_(per_100_ 000_inhabitants)_HLTH18.png [accessed: December 10, 2018].

  • 16

    Torzsa P, Szeiffert L, Dunai K, et al. Diagnosis and therapy of depression in primary care. [A depresszió diagnosztikája és kezelése a családorvosi gyakorlatban.] Orv Hetil. 2009; 150: 1684–1693. [Hungarian]

  • 17

    Willis T. Diabetes: a medical Odyssey. USV Pharmaceutical Corp., Tuckahoe, NY, 1971.

  • 18

    Meurs M, Roest AM, Wolffenbuttel BH, et al. Association of depressive and anxiety disorders with diagnosed versus undiagnosed diabetes: An epidemiological study of 90,686 participants. Psychosom Med. 2016; 78: 233–241.

  • 19

    Anderson RJ, Freedland KE, Clouse RE, et al. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 2001; 24: 1069–1078.

  • 20

    Ali S, Stone MA, Peters JL, et al. The prevalence of co-morbid depression in adults with type 2 diabetes: a systematic review and meta-analysis. Diabet Med. 2006; 23: 1165–1173.

  • 21

    Kivimäki M, Tabák AG, Lawlor DB, et al. Antidepressant use before and after the diagnosis of type 2 diabetes: a longitudinal modeling study. Diabetes Care 2010; 33: 1471–1476.

  • 22

    Rotella F, Mannucci E. Diabetes mellitus as a risk factor for depression. A meta-analysis of longitudinal studies. Diabetes Res Clin Pract. 2013; 99: 98–104.

  • 23

    Eaton WW, Armenian H, Gallo J, et al. Depression and risk for onset of type II diabetes. A prospective population-based study. Diabetes Care 1996; 19: 1097–1102.

  • 24

    Mezuk B, Eaton WW, Albrecht S, et al. Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care 2008; 31: 2383–2390.

  • 25

    Chen S, Zhang Q, Dai G, et al. Association of depression with pre-diabetes, undiagnosed diabetes, and previously diagnosed diabetes: a meta-analysis. Endocrine 2016; 53: 35–46.

  • 26

    Tabák AG, Akbaraly TN, Batty GD, et al. Depression and type 2 diabetes: a causal association? Lancet Diabetes Endocrinol. 2014; 2: 236–245.

  • 27

    Scherrer JF, Xian H, Lustman PJ, et al. A test for common genetic and environmental vulnerability to depression and diabetes. Twin Res Hum Genet. 2011; 14: 169–172.

  • 28

    Mezuk B, Heh V, Prom-Wormley E, et al. Association between major depression and type 2 diabetes in midlife: findings from the Screening Across the Lifespan Twin Study. Psychosom Med. 2015; 77: 559–566.

  • 29

    Kloiber S, Kohli MA, Brueckl T, et al. Variations in tryptophan hydroxylase 2 linked to decreased serotonergic activity are associated with elevated risk for metabolic syndrome in depression. Mol Psychiatry 2010; 15: 736–747.

  • 30

    Nagy G, Ronai Z, Somogyi A, et al. P2RX7 Gln460Arg polymorphism is associated with depression among diabetic patients. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1884–1888.

  • 31

    Agardh E, Allebeck P, Hallqvist J, et al. Type 2 diabetes incidence and socio-economic position: a systematic review and meta-analysis. Int J Epidemiol. 2011; 40: 804–818.

  • 32

    Freeman A, Tyrovolas S, Koyanagi A, et al. The role of socio-economic status in depression: results from the COURAGE (aging survey in Europe). BMC Public Health 2016; 16: 1098.

  • 33

    Berk M, Sarris J, Coulson CE, et al. Lifestyle management of unipolar depression. Acta Psychiatr Scand. 2013; 127(Suppl 443): 38–54.

  • 34

    van Dam RM. The epidemiology of lifestyle and risk for type 2 diabetes. Eur J Epidemiol. 2003; 18: 1115–1125.

  • 35

    Plotsky PM, Owens MJ, Nemeroff CB. Psychoneuroendocrinology of depression. Hypothalamic-pituitary-adrenal axis. Psychiatr Clin North Am. 1998; 21: 293–307.

  • 36

    Chrousos GP. The role of stress and the hypothalamic–pituitary–adrenal axis in the pathogenesis of the metabolic syndrome: neuro-endocrine and target tissue-related causes. Int J Obes Relat Metab Disord. 2000; 24(Suppl 2): S50–S55.

  • 37

    Joseph JJ, Golden SH. Cortisol dysregulation: the bidirectional link between stress, depression, and type 2 diabetes mellitus. Ann N Y Acad Sci. 2017; 1391: 20–34.

  • 38

    Kopczak A, Stalla GK, Uhr M. IGF-I in major depression and antidepressant treatment response. Eur Neuropsychopharmacol. 2015; 25: 864–872.

  • 39

    Friedrich N, Thuesen B, Jørgensen T, et al. The association between IGF-I and insulin resistance: a general population study in Danish adults. Diabetes Care 2012; 35: 768–773.

  • 40

    Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 1998; 41: 1241–1248.

  • 41

    Liu C, Feng X, Li Q, et al. Adiponectin, TNF-α and inflammatory cytokines and risk of type 2 diabetes: a systematic review and meta-analysis. Cytokine 2016; 86: 100–109.

  • 42

    Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010; 67: 446–457.

  • 43

    Laake JP, Stahl D, Amiel SA, et al. The association between depressive symptoms and systemic inflammation in people with type 2 diabetes: findings from the South London Diabetes Study. Diabetes Care 2014; 37: 2186–2192.

  • 44

    Fava M. Weight gain and antidepressants. J Clin Psychiatry 2000; 61(Suppl 11): 37–41.

  • 45

    Kivimäki M, Hamer M, Batty GD, et al. Antidepressant medication use, weight gain, and risk of type 2 diabetes: a population-based study. Diabetes Care 2010; 33: 2611–2616.

  • 46

    Deuschle M. Effects of antidepressants on glucose metabolism and diabetes mellitus type 2 in adults. Curr Opin Psychiatry 2013; 26: 60–65.

  • 47

    Andersohn F, Schade R, Suissa S, et al. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry 2009; 166: 591–598.

  • 48

    Lustman PJ, Griffith LS, Freedland KE, et al. Cognitive behavior therapy for depression in type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med. 1998; 129: 613–621.

  • 49

    Safren SA, Gonzalez JS, Wexler DJ, et al. A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in patients with uncontrolled type 2 diabetes. Diabetes Care 2014; 37: 625–633. Erratum Diabetes Care 2016; 39: 1065.

  • 50

    Ciechanowski PS, Katon WJ, Russo JE. Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. Arch Intern Med. 2000; 160: 3278–3285.

  • 51

    Kivimäki M, Batty GD, Jokela M, et al. Antidepressant medication use and risk of hyperglycemia and diabetes mellitus: a noncausal association? Biol Psychiatry 2011; 70: 978–984.

  • 52

    Deschênes SS, Burns RJ, Pouwer F, et al. Diabetes complications and depressive symptoms: prospective results from the Montreal Diabetes Health and Well-Being Study. Psychosom Med. 2017; 79: 603–612.

  • 53

    Bartoli F, Carrà G, Crocamo C, et al. Association between depression and neuropathy in people with type 2 diabetes: a meta-analysis. Int J Geriatr Psychiatry 2016; 31: 829–836.

  • 54

    Lin EH, Rutter CM, Katon W, et al. Depression and advanced complications of diabetes: a prospective cohort study. Diabetes Care 2010; 33: 264–269.

  • 55

    Park M, Katon WJ, Wolf FM. Depression and risk of mortality in individuals with diabetes: a meta-analysis and systematic review. Gen Hosp Psychiatry 2013; 35: 217–225.

  • 56

    Gold SM, Dziobek I, Sweat V, et al. Hippocampal damage and memory impairments as possible early brain complications of type 2 diabetes. Diabetologia 2007; 50: 711–719.

  • 57

    Moulton CD, Costafreda SG, Horton P, et al. Meta-analyses of structural regional cerebral effects in type 1 and type 2 diabetes. Brain Imaging Behav. 2015; 9: 651–662.

  • 58

    Cole J, Costafreda SG, McGuffin P, et al. Hippocampal atrophy in first episode depression: a meta-analysis of magnetic resonance imaging studies. J Affect Disord. 2011; 134: 483–487.

  • 59

    Rihmer Z, Blazsek P, Hargittay Cs, et al. Depression, anxiety and suicidal behavior. Recognition and care. [Depresszió, szorongás és az öngyilkos magatartás. Felismerés és ellátás.] Lege Artis Med. 2018; 28: 287–292. [Hungarian]

  • 60

    Tabák AG, Herder C, Rathmann W, et al. Prediabetes: a high-risk state for diabetes development. Lancet 2012; 379: 2279–2290.

  • 61

    Herder C, Kowall B, Tabák AG, et al. The potential of novel biomarkers to improve risk prediction of type 2 diabetes. Diabetologia 2014; 57: 16–29.

  • 62

    Torzsa P, Oláh I, Hargittay Cs, et al. Type 2 diabetes: what is the role of a general practitioner in the treatment of diabetes? [2-es típusú cukorbetegség: milyen szerepe van a családorvosnak a betegség kezelésében?] Lege Artis Med. 2018; 28: 533–540. [Hungarian]

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Sep 2020 0 5 12
Oct 2020 0 10 13
Nov 2020 0 19 24
Dec 2020 0 14 30
Jan 2021 0 17 29
Feb 2021 0 10 9
Mar 2021 0 3 4